A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Two Concentrations (0.10%, 0.25%) of HL036 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs HL 036 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors HanAll Biopharma
- 24 Nov 2017 Status changed from not yet recruiting to recruiting.
- 02 Nov 2017 Status changed from planning to not yet recruiting.
- 13 Sep 2017 New trial record